Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
5.2
Journals
Cancers
Special Issues
Cholangiocarcinoma: New Perspectives in Diagnosis and Treatment
share announcement

Cholangiocarcinoma: New Perspectives in Diagnosis and Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 5304

Special Issue Editors

Prof. Dr. Alberta Cappelli

E-Mail Website
Guest Editor
Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy
Interests: cholangiocarcinoma; HCC; role in vascular and hepatobiliary diagnostic and interventional procedures
Special Issues, Collections and Topics in MDPI journals
Dr. Cristina Mosconi

E-Mail Website
Guest Editor
Radiology Unit, Department of Radiology Policlinico di Sant’Orsola IRCCS, Azienda Ospedaliero, Universitaria di Bologna via Albertoni 15, 40138 Bologna, Italy
Interests: cholangiocarcinoma; role in vascular and hepatobiliary diagnostic and interventional procedures
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Though cholangiocarcinoma is a relatively rare biliary adenocarcinoma, its incidence rate has significantly increased over the last several decades. Thankfully, the prognosis of patients has also changed thanks to the advanced diagnostic and treatment approaches to this disease. Management strategies include multidisciplinary treatments, new drugs for systemic chemotherapy, and targeted intra-arterial and surgical therapies. Liver transplantation is also becoming a therapeutic option in select cases. Referrals to centers of excellence and enrolment in novel clinical trials are recommended for patients with unresectable or recurrent disease.

However, as the incidence of this cancer is increasing and more risk factors are being discovered, further efforts are needed to improve outcomes of this unfortunate disease.

This Special Issue provides an overview of cholangiocarcinoma and discusses the currently known risk factors, diagnostic tools, and treatment options with an examination of future approaches.

Dr. Alberta Cappelli
Dr. Cristina Mosconi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cholangiocarcinoma
  • biliary adenocarcinoma
  • diagnosis
  • treatment

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3677 KiB  
Article
Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations
by Tiemo S. Gerber, Lukas Müller, Fabian Bartsch, Lisa-Katharina Gröger, Mario Schindeldecker, Dirk A. Ridder, Benjamin Goeppert, Markus Möhler, Christoph Dueber, Hauke Lang, Wilfried Roth, Roman Kloeckner and Beate K. Straub
Cancers 2022, 14(13), 3156; https://doi.org/10.3390/cancers14133156 - 28 Jun 2022
Cited by 3 | Viewed by 2013
Abstract
Intrahepatic cholangiocarcinomas (iCCAs) may be subdivided into large and small duct types that differ in etiology, molecular alterations, therapy, and prognosis. Therefore, the optimal iCCA subtyping is crucial for the best possible patient outcome. In our study, we analyzed 148 small and 84 [...] Read more.
Intrahepatic cholangiocarcinomas (iCCAs) may be subdivided into large and small duct types that differ in etiology, molecular alterations, therapy, and prognosis. Therefore, the optimal iCCA subtyping is crucial for the best possible patient outcome. In our study, we analyzed 148 small and 84 large duct iCCAs regarding their clinical, radiological, histological, and immunohistochemical features. Only 8% of small duct iCCAs, but 27% of large duct iCCAs, presented with initial jaundice. Ductal tumor growth pattern and biliary obstruction were significant radiological findings in 33% and 48% of large duct iCCAs, respectively. Biliary epithelial neoplasia and intraductal papillary neoplasms of the bile duct were detected exclusively in large duct type iCCAs. Other distinctive histological features were mucin formation and periductal-infiltrating growth pattern. Immunohistochemical staining against CK20, CA19-9, EMA, CD56, N-cadherin, and CRP could help distinguish between the subtypes. To summarize, correct subtyping of iCCA requires an interplay of several factors. While the diagnosis of a precursor lesion, evidence of mucin, or a periductal-infiltrating growth pattern indicates the diagnosis of a large duct type, in their absence, several other criteria of diagnosis need to be combined. Full article
(This article belongs to the Special Issue Cholangiocarcinoma: New Perspectives in Diagnosis and Treatment)
►▼ Show Figures

Figure 1

18 pages, 14042 KiB  
Article
N-Cadherin Distinguishes Intrahepatic Cholangiocarcinoma from Liver Metastases of Ductal Adenocarcinoma of the Pancreas
by Tiemo S. Gerber, Benjamin Goeppert, Anne Hausen, Hagen R. Witzel, Fabian Bartsch, Mario Schindeldecker, Lisa-Katharina Gröger, Dirk A. Ridder, Oscar Cahyadi, Irene Esposito, Matthias M. Gaida, Peter Schirmacher, Peter R. Galle, Hauke Lang, Wilfried Roth and Beate K. Straub
Cancers 2022, 14(13), 3091; https://doi.org/10.3390/cancers14133091 - 23 Jun 2022
Cited by 3 | Viewed by 2525
Abstract
Carcinomas of the pancreatobiliary system confer an especially unfavorable prognosis. The differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and its subtypes versus liver metastasis of ductal adenocarcinoma of the pancreas (PDAC) is clinically important to allow the best possible therapy. We could previously show [...] Read more.
Carcinomas of the pancreatobiliary system confer an especially unfavorable prognosis. The differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and its subtypes versus liver metastasis of ductal adenocarcinoma of the pancreas (PDAC) is clinically important to allow the best possible therapy. We could previously show that E-cadherin and N-cadherin, transmembrane glycoproteins of adherens junctions, are characteristic features of hepatocytes and cholangiocytes. We therefore analyzed E-cadherin and N-cadherin in the embryonally related epithelia of the bile duct and pancreas, as well as in 312 iCCAs, 513 carcinomas of the extrahepatic bile ducts, 228 gallbladder carcinomas, 131 PDACs, and precursor lesions, with immunohistochemistry combined with image analysis, fluorescence microscopy, and immunoblots. In the physiological liver, N-cadherin colocalizes with E-cadherin in small intrahepatic bile ducts, whereas larger bile ducts and pancreatic ducts are positive for E-cadherin but contain decreasing amounts of N-cadherin. N-cadherin was highly expressed in most iCCAs, whereas in PDACs, N-cadherin was negative or only faintly expressed. E- and N-cadherin expression in tumors of the pancreaticobiliary tract recapitulate their expression in their normal tissue counterparts. N-cadherin is a helpful marker for the differential diagnosis between iCCA and PDAC, with a specificity of 96% and a sensitivity of 67% for small duct iCCAs and 50% for large duct iCCAs. Full article
(This article belongs to the Special Issue Cholangiocarcinoma: New Perspectives in Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop